News
QTTB
8.71
-1.25%
-0.11
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 1d ago
Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London
PR Newswire · 2d ago
Weekly Report: what happened at QTTB last week (1102-1106)?
Weekly Report · 4d ago
Leerink Partners Reaffirms Their Buy Rating on Q32 Bio (QTTB)
TipRanks · 11/05 14:30
Q32 Bio (QTTB) Gets a Buy from Morgan Stanley
TipRanks · 11/05 13:46
Oppenheimer Reaffirms Their Buy Rating on Q32 Bio (QTTB)
TipRanks · 11/05 13:27
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Siemens Healthineers AG (OtherSEMHF) and Q32 Bio (QTTB)
TipRanks · 11/05 12:40
Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata
NASDAQ · 11/04 18:11
Analysts Are Bullish on These Healthcare Stocks: Faeth Therapeutics (FTH), Q32 Bio (QTTB)
TipRanks · 11/04 18:01
Q32 Bio GAAP EPS of -$0.26 beats by $0.07
Seeking Alpha · 11/04 12:12
Q32 Bio Q3 EPS $(0.26) Beats $(0.31) Estimate
Benzinga · 11/04 12:05
*Q32 Bio 3Q Research and Development Expenses $5.1M >QTTB
Dow Jones · 11/04 12:01
*Q32 Bio 3Q Loss/Shr 26c >QTTB
Dow Jones · 11/04 12:00
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire · 11/04 11:59
Press Release: Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 11/04 11:59
Q32 Bio: Q3 Earnings Snapshot
Barchart · 11/04 06:11
Weekly Report: what happened at QTTB last week (1026-1030)?
Weekly Report · 11/02 09:27
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:12
Weekly Report: what happened at QTTB last week (1019-1023)?
Weekly Report · 10/26 09:27
Weekly Report: what happened at QTTB last week (1012-1016)?
Weekly Report · 10/19 09:27
More
Webull provides a variety of real-time QTTB stock news. You can receive the latest news about Q32 BIO INC through multiple platforms. This information may help you make smarter investment decisions.
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.